Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study

Nakasone,Yasushi; Watabe,Kazunori; Watanabe,Keita; Tomonaga,Akihito; Nagaoka,Isao; Yamamoto,Tetsuro; Yamaguchi,Hideyo

doi:10.3892/etm.2011.298

Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study

Authors:
- Yasushi Nakasone
- Kazunori Watabe
- Keita Watanabe
- Akihito Tomonaga
- Isao Nagaoka
- Tetsuro Yamamoto
- Hideyo Yamaguchi
View Affiliations

Affiliations: Kenkoukazoku, Inc., Kagoshima 892-0848, Japan, Kitashinyokohama Orthopedic Surgery, Kohoku-ku, Yokohama 223-0059, Japan, Tana Orthopedic Surgery, Aoba-ku, Yokohama 227-0064, Japan, Department of Host Defense and Biochemical Research, Juntendo University, Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan, Research Center, TTC Co., Ltd., Shibuya-ku, Tokyo 150-0021, Japan
Published online on: June 27, 2011 https://doi.org/10.3892/etm.2011.298
Pages: 893-899

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we aimed to investigate the potential effect of a glucosamine (1,200 mg/day)-based dietary supplement combined with chondroitin sulfate and three antioxidant micronutrients, namely methylsulfonylmethane, guava leaf extract, and vitamin D (test supplement) on osteoarthritis (OA) of the knee. A 16-week, randomized, double-blinded, placebo-controlled trial was conducted involving 32 subjects with symptomatic knee OA. Clinical outcomes were measured using the Japanese Knee Osteoarthritis Measure (JKOM) for symptoms and a study diary-based visual analog scale (diary VAS) for pain at baseline and at weeks 4, 8, 12 and 16 during the 16-week intervention period. Furthermore, biomarkers for cartilage type II collagen degradation (C2C) and synovitis hyaluronan (HA) were measured. As compared with the baseline, the JKOM pain subscale was significantly improved at all of the four assessment time points in the test group, but was not at any time point in the placebo group. On the other hand, all of the four symptom subscales and the aggregated total symptoms were significantly improved in the two groups at one or more time points. However, all of these clinical improvements were greater in extent in the test group than in the placebo group, and there were significant differences between groups in the magnitude of changes from baseline for one subscale 'general activities' and the aggregated total symptoms at week 8 (P<0.05). The results of efficacy assessments with the diary VAS showed that all of the three pain subscales were significantly improved only in the test group at almost all the time points. Moreover, serum levels of C2C and HA were decreased by 10 and 25%, respectively, at week 16 in the test group, albeit not statistically significant, without any detectable changes in the placebo group. In conclusion, although the results obtained in this study were not conclusive, the tested glucosamine-based combination supplement is likely to have a beneficial effect on pain and other symptoms associated with knee OA.

View Figures

View References

1.	Ravenda V, Manette C, Lemmens R, Mariani AM, Struvay N and Reginster JY: Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res. 19:55–60. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Jinks C, Jordan K and Croft P: Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 46:877–881. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K and Akune T: Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 27:620–628. 2009. View Article : Google Scholar
4.	Eccles M, Freemantle N and Mason J: North of England evidence-based guidelines development project: summary guidelines for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. North of England Non-steroidal Anti-inflammatory Drug Guidelines Development Group. BMJ. 317:526–530. 1998.
5.	Wieland HA, Michaelis M, Kirschbaum BJ and Rudolphi KA: Osteoarthritis: an untreatable disease? Nat Rev Drug Discov. 4:331–344. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Rashad S, Revell P, Hemingway A, Low F, Rainford K and Walker F: Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 2:519–522. 1989. View Article : Google Scholar : PubMed/NCBI
7.	Adams ME, Lussier AJ and Peyron JG: A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of knee osteoarthritis. Drug Saf. 23:115–130. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M and Kessler RC: Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 280:1569–1575. 1998.
9.	Rao JK, Mihaliak K, Kroenke K, Bradley J, Tiemey WM and Weinberger M: Use of complementary therapies for arthritis among patients of rheumatologists. Am Intern Med. 131:409–416. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Astin JA: Why patients use alternative medicine: results of a national study. JAMA. 279:1548–1553. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Bellamy N and Buchanan WW: Outcome measurement in osteoarthritis clinical trials: the case for standardization. Clin Rheumatol. 3:293–305. 1984. View Article : Google Scholar : PubMed/NCBI
12.	Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP and Altman R: Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl. 41:65–71. 1994.PubMed/NCBI
13.	Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:2113–2123. 2002.PubMed/NCBI
14.	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
15.	McAlindon TE, La Valley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y and Reginster JY: Structural and symptomatic efficacy of glucosamine and chondroitin sulfate in knee osteoarthritis. A comprehensive meta-analysis. Arch Intern Med. 163:1514–1522. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO III, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW and Williams HJ: Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis. N Engl J Med. 354:795–808. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Natural Medicines Comprehensive Database: 8th edition. Therapeutic Research Faculty; Stockton, CA: 2006, http://www.naturaldatabase.comuri. (Accessed April 21, 2011).
19.	Rosenbaum CC, O'Mathúna DP, Chavez M and Shields K: Antioxidants and anti-inflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Altern Ther Health Med. 16:32–40. 2010.PubMed/NCBI
20.	Loeser RF, Carlson CS, Del Carlo M and Cole A: Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1 beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum. 46:2349–2357. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T and Nishioka K: Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and down-regulation of chondrocyte function. Arthritis Res Ther. 7:R380–R391. 2005. View Article : Google Scholar
22.	Henrotin Y, Deby-Dupont G, Deby C, De Bruyn M, Lamy M and Franchimont P: Production of active oxygen species by isolated human chondrocytes. Br J Rheumatol. 32:562–567. 1993. View Article : Google Scholar : PubMed/NCBI
23.	Henrotin Y, Deby-Dupont G, Deby C, Franchimont P and Emerit I: Active oxygen species, articular inflammation and cartilage damage. EXS. 62:308–322. 1992.PubMed/NCBI
24.	Martin JA and Buckwalter JA: Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology. 3:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Usha PR and Naidu MU: Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest. 24:353–363. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Kim LS, Axelrod LJ, Howard P, Buratovich N and Waters RF: Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 14:286–294. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Ojewole JA: Antiinflammatory and analgesic effects of Psidium guajava Linn. (Myrtaceae) leaf acqueous extract in rats and mice. Methods Find Exp Clin Pharmacol. 28:441–446. 2006.
28.	McAlindon TE, Jaques P, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Levy D and Felson DT: Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum. 39:648–656. 1996. View Article : Google Scholar : PubMed/NCBI
29.	McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Wilson PW and Jacques P: Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med. 125:353–359. 1996. View Article : Google Scholar : PubMed/NCBI
30.	Rizkalla G, Reiner A, Bogoch E and Poole AR: Studies on the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 90:2268–2277. 1992. View Article : Google Scholar
31.	Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, Sakai T, Wahl C, El-Maadaway S, Webb G, Tchetina E and Wu W: Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 61(Suppl 2): S78–S81. 2002. View Article : Google Scholar : PubMed/NCBI
32.	Bassleer C, Ravati L and Frachimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage. 6:427–434. 1998. View Article : Google Scholar
33.	Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M and Vignon E: Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 8:207–212. 2000. View Article : Google Scholar : PubMed/NCBI
34.	Lipiello L, Woodward J, Karpman R and Hammand TA: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res. 381:229–240. 2000. View Article : Google Scholar : PubMed/NCBI
35.	Oegema TR, Deloria LB, Sandy JD and Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knee of young rabbits. Arthritis Rheum. 46:2495–2503. 2002. View Article : Google Scholar : PubMed/NCBI
36.	Uebelhart D, Thonar EJ, Zhang J and Williams JM: Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 6(Suppl 1): S6–S13. 1998. View Article : Google Scholar : PubMed/NCBI
37.	Christgau S, Henrotin Y, Tankó LB, Rovati LC, Collette J, Bruyere O, Deroisy R and Reginster JY: Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulfate. Clin Exp Rheumatol. 22:36–42. 2004.
38.	Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Grant E, Lobanok T, Ionescu M, Poole AR and Esdaile JM: Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol. 32:896–902. 2005.
39.	Mazières B, Hucher M, Zaïm M and Garnero P: Effect of chondroitin sulfate in symptomatic knee osteoarthritis: a multicentre, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 66:639–645. 2007.
40.	Wells AF, Klareskog L, Lindblad S and Laurent TC: Correlation between increased hyaluronan localized in arthritic synovium and the presence of proliferating cells: a role for macrophage-derived factors. Arthritis Rheum. 35:391–396. 1992. View Article : Google Scholar
41.	Vilim V, Vytásek R, Olejárová M, Machácek S, Gatterová J, Procházka B, Kraus VB and Pavelka K: Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage. 9:612–618. 2001. View Article : Google Scholar : PubMed/NCBI
42.	Kellgren JH and Lawrence JS: Radiological assessment of osteoarthritis. Ann Rheum Dis. 16:494–502. 1957. View Article : Google Scholar
43.	Akai M, Doi T, Fujino K, Iwaya T, Kurosawa H and Nasu T: An outcome measure for Japanese people with knee osteoarthritis. J Rheumatol. 32:1524–1532. 2005.PubMed/NCBI
44.	International Classification of Functioning, Disability and Health. World Health Organization; Geneva: 2001
45.	Akai M, Iwaya T, Kurosawa H, Doi T, Nasu T, Hayashi K and Fujino K: Development of new disease-specific QOL measure for patients with knee osteoarthritis. Japanese Knee Osteoarthritis Measure (JKOM). J Phys Med. 16:55–62. 2005.
46.	Lewis B, Lewis D and Cumming G: The comparative analgesic efficacy of transcutaneous electric nerve stimulation and a nonsteroidal anti-inflammatory drug for painful osteoarthritis. Br J Rheumatol. 33:455–460. 1994. View Article : Google Scholar : PubMed/NCBI
47.	Pham T, Van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T and Dougados M; OMERACT-OARSI: Outcome variables for osteoarthritis clinical trial: the OMERACT-OARSI set of responder criteria. J Rheumatol. 30:1648–1654. 2003.PubMed/NCBI
48.	Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P and Uebelhart D: Chondroitins 4 and 6 sulphate in osteoarthritis of the knee: a randomized, controlled trial. Arthiritis Rheum. 52:779–786. 2005. View Article : Google Scholar : PubMed/NCBI
49.	Garnero P and Delmas PD: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 15:641–646. 2003. View Article : Google Scholar
50.	Kraus VB: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 17:641–646. 2005. View Article : Google Scholar
51.	Garnero P, Ayral X, Rousseau FC, Christgau S, Sandell LJ, Dougados M and Delmas PD: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 46:2613–2624. 2002. View Article : Google Scholar : PubMed/NCBI
52.	Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG and Pols HA: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 50:2471–2478. 2004. View Article : Google Scholar : PubMed/NCBI
53.	Poole AR, Ionescu M, Fitzcharles MA and Billinghurst RC: The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods. 294:145–153. 2004. View Article : Google Scholar : PubMed/NCBI
54.	Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J and Dieppe P: Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum. 38:760–767. 1995. View Article : Google Scholar : PubMed/NCBI
55.	Pavelka K, Forejtová S, Olejárová M, Gatterová J, Senolt L, Spacek P, Braun M, Hulejová M, Stovicková J and Pavelková A: Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage. 12:277–283. 2004. View Article : Google Scholar : PubMed/NCBI
56.	Mazières B, Garnero P, Guéguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Sallles JP, Vignon E and Dougados M: Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis. 65:354–359. 2006.PubMed/NCBI
57.	Ayral X, Pickering EH, Woodworth TG, Mackillop N and Dougados M: Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage. 13:361–367. 2005.
58.	Saari H, Sorsa T, Lindy O, Sumalainen K, Halinen S and Konttinen YT: Reactive oxygen species as regulators of human neutrophil and fibroblast interstitial collagenases. Int J Tissue React. 14:113–120. 1992.PubMed/NCBI
59.	Saari H, Konttinen YT, Friman C and Sorsa T: Differential effects of reactive oxygen species on native synovial fluid and purified human umbrical cord hyaluronate. Inflammation. 17:403–415. 1993. View Article : Google Scholar : PubMed/NCBI